The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to ...
according to J&J's pharma unit Janssen. Maintaining remission at 32 weeks was a key secondary endpoint, hit by 55% of the Spravato group and 37% of patients taking quetiapine, with the proportion ...
Johnson & Johnson announced that the U.S. FDA has granted investigational nipocalimab Fast Track designation for the treatment of adult ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback